Good news, but be aware it may still take over a year for the Medicare coverage process to be completed and nationwide coverage to begin (see below). The panel's recommendation is the first step - which began when a request for a national Medicare coverage decision was filed by Barry Green, a PWP from Texas, in Oct 2001. SEE: www.grassrootsconnection.com for more info. on this issue Medtronics Press release FROM: Business Wire June 12, 2002, Wednesday 02:56 PM Eastern Time SECTION: HEALTHWIRE DISTRIBUTION: Business Editors & Health/Medical Writers HEADLINE: Medicare Panel to Recommend National Coverage of Brain Stimulation for Parkinson's and Tremor; Clinical Data and Expert Testimony Highlight Benefits of Activa Therapy from Medtronic DATELINE: BALTIMORE, June 12, 2002 The approximately 2.5 million Americans with Parkinson's disease or Essential Tremor received good news today as a Medicare panel prepares to recommend national coverage for brain stimulation to treat advanced stages of the two most common neurological movement disorders. After considering clinical data and expert testimony, the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee (MCAC) overwhelmingly affirmed the effectiveness of Activa(R) Therapy, which uses brain stimulation technology developed by Medtronic, Inc. (NYSE:MDT) to relieve symptoms of Parkinson's disease and Essential Tremor when medication alone fails to provide adequate benefit or consistently causes intolerable side effects. Based on the prevalence and progression of the diseases, as well as their responsiveness to medication, Medtronic estimates that about 85,000 Parkinson's patients and 5,000 Essential Tremor patients in the United States are candidates for treatment with Activa Therapy. "The panel's affirmation validates a growing accumulation of effectiveness data and, equally as important, the experience of thousands of patients whose motor function and overall lives have been dramatically improved through treatment with brain stimulation," said Dr. Erwin B. Montgomery, a movement disorders neurologist and co-director of the Cleveland Clinic Foundation's Functional and Restorative Neuroscience Center. "National Medicare coverage and adequate reimbursement are critical next steps in assuring access to this treatment for the thousands more patients who stand to benefit from it." Dr. Montgomery addressed the MCAC panel with Dr. Roy Bakay, professor of neurological surgery at Rush-Presbyterian-St. Luke's Medical Center in Chicago. Their presentation noted key findings of a global clinical study of brain stimulation for advanced Parkinson's disease symptoms after one year of treatment: -- 87 percent of patients, assessed without the benefit of medication, demonstrated improved motor function -- on average, patients gained an additional six hours of good motor function each day Today's panel meeting at the Baltimore Convention Center also included discussion of a technology assessment report on Activa Therapy prepared by the Blue Cross and Blue Shield Association. "The published scientific evidence is compelling because of the numbers of consecutively treated patients described, the consistency of the findings across studies, and the magnitude of clinical improvements observed on standardized rating scales of neurologic function," according to the report by Dr. Joan B. Vatz, who reviewed results of 33 separate studies for the assessment. "More recent evidence suggests that bilateral deep-brain stimulation ... may alleviate ... parkinsonian symptoms (tremor, rigidity, and bradykinesia)." MCAC's executive committee is scheduled to meet Sept. 25 to ratify its expert panel's recommendation. Following receipt of the executive committee's recommendation, the Centers for Medicare and Medicaid Services (CMS) will decide within 60 days whether to establish a national Medicare coverage policy for Activa Therapy. CMS will then publish its decision online at www.cms.hhs.gov/coverage/. If the decision is positive, CMS will issue a national coverage decision within 60 days and begin to develop implementation instructions for its contractors (carriers and fiscal intermediaries). These instructions will provide details regarding coverage, coding and reimbursement levels. Typically, it requires seven to nine months from the date of the national coverage decision for the policy to go into effect. CMS (formerly the Health Care Financing Administration) is the government agency that administers Medicare and Medicaid, two bellwethers in health insurance that, combined, cover an estimated 75 million Americans. All 52 Medicare jurisdictions now have written policies providing coverage for Activa Tremor Control Therapy, which stimulates the thalamus to suppress tremor. But less than half have written policies in place for Activa Parkinson's Control Therapy, which stimulates other structures -- namely, the subthalamic nucleus (STN) or the globus pallidus pars interna (GPi) -- to reduce the typically more debilitating symptoms of the disease, including stiffness and slowness. A national coverage policy for Activa Therapy would eliminate the need for individual action by the jurisdictions that do not have written policies for Activa Parkinson's Control Therapy. Essential Tremor and Parkinson's disease are the two most common neurological movement disorders. Essential Tremor afflicts about 1.5 million Americans; Parkinson's disease, about 1 million. Tremor is a common symptom of both, but Parkinson's also causes rigidity, slowness of movement and poor balance. Nearly 8,000 people in the United States have been treated with Activa Therapy -- about 6,000 for symptoms of advanced Parkinson's disease and another 2,000 for Essential Tremor. Activa Tremor Control Therapy received approval from the U.S. Food and Drug Administration (FDA) in August 1997 for unilateral stimulation of the thalamus to suppress tremor on the opposite side of the body. Activa Parkinson's Control Therapy received FDA approval in January 2002 for bilateral stimulation of the STN or GPi to reduce symptoms of advanced Parkinson's disease. The cost of Activa Therapy ranges from $25,000 to$30,000 per side for the device and the associated physician and hospital fees. Editor's Note: Additional information and graphics related to Activa Therapy are available online at www.activapresspage.com. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn